Related references
Note: Only part of the references are listed.Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway
Ke Sai et al.
JOURNAL OF NEURO-ONCOLOGY (2012)
Cytoreductive surgery of glioblastoma as the key to successful adjuvant therapies: new arguments in an old discussion
Walter Stummer et al.
ACTA NEUROCHIRURGICA (2011)
AVAglio: Phase 3 Trial of Bevacizumab Plus Temozolomide and Radiotherapy in Newly Diagnosed Glioblastoma Multiforme
O. L. Chinot et al.
ADVANCES IN THERAPY (2011)
A Dual PI3K/mTOR Inhibitor, PI-103, Cooperates with Stem Cell-Delivered TRAIL in Experimental Glioma Models
Tugba Bagci-Onder et al.
CANCER RESEARCH (2011)
Nimotuzumab for pediatric diffuse intrinsic pontine gliomas
Maura Massimino et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2011)
Antiangiogenic therapy for patients with glioblastoma: current challenges in imaging and future directions
Manmeet S. Ahluwalia et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2011)
Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study
John F. de Groot et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase II study of sunitinib malate in patients with recurrent high-grade glioma
B. Neyns et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Phase I study of sunitinib and irinotecan for patients with recurrent malignant glioma
David A. Reardon et al.
JOURNAL OF NEURO-ONCOLOGY (2011)
Pathway inhibition: emerging molecular targets for treating glioblastoma
Wolfgang Wick et al.
NEURO-ONCOLOGY (2011)
Clinical trial end points for high-grade glioma: the evolving landscape
David A. Reardon et al.
NEURO-ONCOLOGY (2011)
A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma
Patrick Y. Wen et al.
NEURO-ONCOLOGY (2011)
A Novel Extracellular Hsp90 Mediated Co-Receptor Function for LRP1 Regulates EphA2 Dependent Glioblastoma Cell Invasion
Udhayakumar Gopal et al.
PLOS ONE (2011)
Perifosine and CCI 779 Co-Operate to Induce Cell Death and Decrease Proliferation in PTEN-Intact and PTEN-Deficient PDGF-Driven Murine Glioblastoma
Kenneth L. Pitter et al.
PLOS ONE (2011)
Notch signaling in glioblastoma: a developmental drug target?
Maria Maddalena Lino et al.
BMC MEDICINE (2010)
Targeting SRC in glioblastoma tumors and brain metastases Rationale and preclinical studies
Manmeet S. Ahluwalia et al.
CANCER LETTERS (2010)
γ-Secretase Inhibitors Enhance Temozolomide Treatment of Human Gliomas by Inhibiting Neurosphere Repopulation and Xenograft Recurrence
Candace A. Gilbert et al.
CANCER RESEARCH (2010)
Integrin Alpha 6 Regulates Glioblastoma Stem Cells
Justin D. Lathia et al.
CELL STEM CELL (2010)
Therapeutic targeting of EGFR in malignant gliomas
Fei Ye et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2010)
Cilengitide in newly diagnosed glioblastoma with MGMT promoter methylation: Protocol of a multicenter, randomized, open-label, controlled phase III trial (CENTRIC)
R. Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase I/IIa Study of Cilengitide and Temozolomide With Concomitant Radiotherapy Followed by Cilengitide and Temozolomide Maintenance Therapy in Patients With Newly Diagnosed Glioblastoma
Roger Stupp et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase III Study of Enzastaurin Compared With Lomustine in the Treatment of Recurrent Intracranial Glioblastoma
Wolfgang Wick et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Phase 1 clinical trial of bortezomib in adults with recurrent malignant glioma
Surasak Phuphanich et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
ZD6474, a Multitargeted Inhibitor for Receptor Tyrosine Kinases, Suppresses Growth of Gliomas Expressing an Epidermal Growth Factor Receptor Mutant, EGFRvIII, in the Brain
Jia-Jean Yiin et al.
MOLECULAR CANCER THERAPEUTICS (2010)
A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy
Jeffrey J. Raizer et al.
NEURO-ONCOLOGY (2010)
Enzastaurin plus temozolomide with radiation therapy in glioblastoma multiforme: A phase I study
Nicholas Butowski et al.
NEURO-ONCOLOGY (2010)
Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma
Fabio M. Iwamoto et al.
NEURO-ONCOLOGY (2010)
Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma
Sith Sathornsumetee et al.
NEURO-ONCOLOGY (2010)
Progress on Antiangiogenic Therapy for Patients with Malignant Glioma
Manmeet S. Ahluwalia et al.
JOURNAL OF ONCOLOGY (2010)
Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma
B. Neyns et al.
ANNALS OF ONCOLOGY (2009)
Boron neutron capture therapy of EGFR or EGFRvIII positive gliomas using either boronated monoclonal antibodies or epidermal growth factor as molecular targeting agents
W. Yang et al.
APPLIED RADIATION AND ISOTOPES (2009)
Monoclonal Antibodies Targeting Vascular Endothelial Growth Factor Current Status and Future Challenges in Cancer Therapy
Jerry Y. Hsu et al.
BIODRUGS (2009)
Convection-enhanced delivery of nanocarriers for the treatment of brain tumors
Emilie Allard et al.
BIOMATERIALS (2009)
Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma
D. A. Reardon et al.
BRITISH JOURNAL OF CANCER (2009)
Phase I Pharmacokinetic Study of the Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor Vatalanib (PTK787) Plus Imatinib and Hydroxyurea for Malignant Glioma
David A. Reardon et al.
CANCER (2009)
Acquired Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancers Dependent on the Epidermal Growth Factor Receptor Pathway
Kim-Son H. Nguyen et al.
CLINICAL LUNG CANCER (2009)
Nimotuzumab: a novel anti-EGFR monoclonal antibody that retains anti-EGFR activity while minimizing skin toxicity
William Kells Boland et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2009)
Edema Control by Cediranib, a Vascular Endothelial Growth Factor Receptor-Targeted Kinase Inhibitor, Prolongs Survival Despite Persistent Brain Tumor Growth in Mice
Walid S. Kamoun et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Vorinostat in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study
Evanthia Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034
Martin J. van den Bent et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Interactions between PTEN and the c-Met pathway in glioblastoma and implications for therapy
Yunqing Li et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial
Roger Stupp et al.
LANCET ONCOLOGY (2009)
Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells
Claire Marie-Elisabeth Sauvageot et al.
NEURO-ONCOLOGY (2009)
IDH1 and IDH2 Mutations in Gliomas
Hai Yan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The Plasticity of Oncogene Addiction: Implications for Targeted Therapies Directed to Receptor Tyrosine Kinases
Vinochani Pillay et al.
NEOPLASIA (2009)
Integrins - The keys to unlocking angiogenesis
Rita Silva et al.
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY (2008)
HIF1α induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion
Rose Du et al.
CANCER CELL (2008)
Targeting cancer stem cells through L1CAM suppresses glioma growth
Shideng Bao et al.
CANCER RESEARCH (2008)
Deconstructing feedback-signaling networks to improve anticancer therapy with mTORC1 inhibitors
Arkaitz Carracedo et al.
CELL CYCLE (2008)
A phase I dose-escalation study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of a novel PI3K inhibitor, XL765, administered orally to patients (pts) with advanced solid tumors
K. P. Papadopoulos et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Randomized Phase II Study of Cilengitide, an Integrin-Targeting Arginine-Glycine-Aspartic Acid Peptide, in Recurrent Glioblastoma Multiforme
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase II study of imatinib in patients with recurrent gliomas of various histologies: A European organisation for research and treatment of cancer brain tumor group study
Eric Raymond et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Irinotecan and bevacizumab in progressive primary brain tumors, an evaluation of efficacy and safety
Tyler Y. Kang et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Progression-free survival: An important end point in evaluating therapy for recurrent high-grade gliomas
Kathleen R. Lamborn et al.
NEURO-ONCOLOGY (2008)
VEGF Trap induces antiglioma effect at different stages of disease
Candelaria Gomez-Manzano et al.
NEURO-ONCOLOGY (2008)
Bevacizumab for recurrent malignant gliomas - Efficacy, toxicity, and patterns of recurrence
A. D. Norden et al.
NEUROLOGY (2008)
Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-Deficient glioblastoma
Tim F. Cloughesy et al.
PLOS MEDICINE (2008)
Tumour vascularization: sprouting angiogenesis and beyond
Femke Hillen et al.
CANCER AND METASTASIS REVIEWS (2007)
Inhibition of angiogenesis and invasion in malignant gliomas
Andrew Chi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2007)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Angiogenesis in brain tumours
Rakesh K. Jain et al.
NATURE REVIEWS NEUROSCIENCE (2007)
Molecularly targeted therapy for malignant glioma
Sith Sathornsumetee et al.
CANCER (2007)
Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma
Christopher E. Pelloski et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism
X. Wan et al.
ONCOGENE (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Synergistic antiglioma activity of radiotherapy and enzastaurin
Ghazaleh Tabatabai et al.
ANNALS OF NEUROLOGY (2007)
PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors
Ingo K. Mellinghoff et al.
CLINICAL CANCER RESEARCH (2007)
Cyclopamine-mediated hedgehog pathway inhibition depletes stem-like cancer cells in glioblastoma
Eli E. Bar et al.
STEM CELLS (2007)
Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity
Cory Allen et al.
CANCER RESEARCH (2006)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Marked genomic differences characterize primary and secondary glioblastoma subtypes and identify two distinct molecular and clinical secondary glioblastoma entities
Elizabeth A. Maher et al.
CANCER RESEARCH (2006)
Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2006)
Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor
Shideng Bao et al.
CANCER RESEARCH (2006)
Integrin αVβ3 antagonist Cilengitide enhances efficacy of radiotherapy in endothelial cell and non-small-cell lung cancer models
Jeffrey M. Albert et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study
Timothy F. Cloughesy et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Treatment of primary glioblastoma multiforme with cetuximab, radiotherapy and temozolomide (GERT) - phase I/II trial: study protocol
Stephanie E. Combs et al.
BMC CANCER (2006)
Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial
W Stummer et al.
LANCET ONCOLOGY (2006)
Changing paradigms - An update on the multidisciplinary management of malignant glioma
Roger Stupp et al.
ONCOLOGIST (2006)
Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma
MD Prados et al.
NEURO-ONCOLOGY (2006)
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
S Minucci et al.
NATURE REVIEWS CANCER (2006)
Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent glioblastorna multiforme
DA Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Akt blocks breast cancer cell motility and invasion through the transcription factor NFAT
M Yoeli-Lerner et al.
MOLECULAR CELL (2005)
Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors
IK Mellinghoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Biomarkers to predict response to epidermal growth factor receptor inhibitors
DA Haas-Koogan et al.
CELL CYCLE (2005)
Imatinib and hydroxyurea in pretreated progressive glioblastoma multiforme: a patient series
G Dresemann
ANNALS OF ONCOLOGY (2005)
Scatter factor/hepatocyte growth factor in brain tumor growth and angiogenesis
R Abounader et al.
NEURO-ONCOLOGY (2005)
Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: A north central cancer treatment group study
E Galanis et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme
SM Chang et al.
INVESTIGATIONAL NEW DRUGS (2005)
Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib
DA Haas-Kogan et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2005)
Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas
H Ohgaki et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2005)
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib
EL Kwak et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme
Y Liang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
MGMT gene silencing and benefit from temozolomide in glioblastoma
ME Hegi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
R Stupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients
AB Heimberger et al.
CLINICAL CANCER RESEARCH (2005)
Anti-epidermal growth factor receptor monoclonal antibody cetuximab augments radiation effects in glioblastoma multiforme in vitro and in vivo
JL Eller et al.
NEUROSURGERY (2005)
Integrins: roles in cancer development and as treatment targets
H Jin et al.
BRITISH JOURNAL OF CANCER (2004)
Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma
R Galli et al.
CANCER RESEARCH (2004)
Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer
R Pérez-Soler et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
PDGF receptors-mediators of autocrine tumor growth and regulators of tumor vasculature and stroma
A Östman
CYTOKINE & GROWTH FACTOR REVIEWS (2004)
Targeting the mitogen-activated protein kinase cascade to treat cancer
JS Sebolt-Leopold et al.
NATURE REVIEWS CANCER (2004)
Prognostic factors for survival of patients with glioblastoma: Recursive partitioning analysis
KR Lamborn et al.
NEURO-ONCOLOGY (2004)
Intussusceptive angiogenesis: Its emergence, its characteristics, and its significance
PH Burri et al.
DEVELOPMENTAL DYNAMICS (2004)
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
H Hurwitz et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Suppression of angiogenesis and tumor growth by selective inhibition of angiopoietin-2
J Oliner et al.
CANCER CELL (2004)
Phase II trial of gefitinib in recurrent glioblastoma
JN Rich et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
Molecular mechanisms of glioma cell migration and invasion
T Demuth et al.
JOURNAL OF NEURO-ONCOLOGY (2004)
A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer
JC Yang et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for Bcr/Abl-induced leukemia
NC Wolff et al.
BLOOD (2003)
Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors
G Bergers et al.
JOURNAL OF CLINICAL INVESTIGATION (2003)
Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen
TF Cloughesy et al.
CANCER (2003)
Distribution of STI-571 to the brain is limited by P-glycoprotein-mediated efflux
HQ Dai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2003)
Interaction of Hsp90 with the nascent form of the mutant epidermal growth factor receptor EGFRvIII
SJ Lavictoire et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Histone deacetylases inhibitors as anti-angiogenic agents altering vascular endothelial growth factor signaling
CF Deroanne et al.
ONCOGENE (2002)
Phase II study of Thalidomide in the treatment of recurrent glioblastoma multiforme
GM Marx et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Activation of the HIF pathway in cancer
PH Maxwell et al.
CURRENT OPINION IN GENETICS & DEVELOPMENT (2001)
Untangling the ErbB signalling network
Y Yarden et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2001)
Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption
JL Rubenstein et al.
NEOPLASIA (2000)
Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas
HA Fine et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
WKA Yung et al.
BRITISH JOURNAL OF CANCER (2000)
Share Paper
